Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precision BioSciences, Inc. on September 21, 2020. The filing discloses a new clinical trial collaboration agreement entered into with SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a strategic partnership announcement.
Material Changes and Strategic Developments
- Collaboration Agreement: Precision BioSciences and SpringWorks Therapeutics agreed to evaluate PBCAR269A (an investigational allogeneic CAR T cell therapy targeting BCMA) in combination with nirogacestat (SpringWorks' investigational gamma secretase inhibitor).
- Target Indication: The combination therapy will be tested in patients with relapsed or refractory multiple myeloma.
- Study Design: The collaboration involves an expanded Phase 1/2a study. Precision BioSciences will assume all development costs for this expanded study.
- Governance: A joint development committee will be formed to oversee the clinical study.
- Timeline: The study is expected to commence in the first quarter of 2021, pending regulatory discussions.
Outlook, Risks, and Management Commentary
Management issued forward-looking statements regarding the expected timing of the study commencement and the potential of the collaboration. The filing explicitly references the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2020, for a comprehensive list of risks, uncertainties, and factors that could cause actual results to differ from expectations. The Company stated it does not plan to publicly update forward-looking statements except as required by law.
Key Facts for Investor Verification
- Verify the specific terms of the collaboration agreement regarding cost-sharing and intellectual property rights in the full press release (Exhibit 99.1).
- Confirm the regulatory status of nirogacestat and PBCAR269A individually prior to the combination study.
- Review the Form 10-Q for the quarter ended June 30, 2020, to assess the Company's current cash position and ability to fund the assumed development costs.
- Monitor the timeline for the first quarter 2021 study commencement and any regulatory feedback received.